Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
Joint Authors
Chaucer, Benjamin
Stone, Abriella
Demanes, Augustus
Seibert, Shawn M.
Source
Case Reports in Oncological Medicine
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-01-17
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
The treatment of cancer is a rapidly evolving field.
As more chemotherapeutic agents become available, reporting the side effects of these agents in clinical practice becomes increasingly important.
Nivolumab is one of the chemotherapeutic agents commonly used for treatment of renal cell carcinoma, metastatic melanoma, and metastatic non-small cell lung cancer.
While common side effects are known and well documented, encephalitis is documented as an extremely rare side effect.
We present the case of an extremely rare side effect to a common chemotherapeutic agent.
American Psychological Association (APA)
Chaucer, Benjamin& Stone, Abriella& Demanes, Augustus& Seibert, Shawn M.. 2018. Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Case Reports in Oncological Medicine،Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1146361
Modern Language Association (MLA)
Chaucer, Benjamin…[et al.]. Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Case Reports in Oncological Medicine No. 2018 (2018), pp.1-3.
https://search.emarefa.net/detail/BIM-1146361
American Medical Association (AMA)
Chaucer, Benjamin& Stone, Abriella& Demanes, Augustus& Seibert, Shawn M.. Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Case Reports in Oncological Medicine. 2018. Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1146361
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146361
